JPRN-jRCT2080225226已完成Unknown
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
oxo Oncology, Inc.,Wholly owned subsidiary of Eli Lilly and Company / CMIC Co., Ltd.0 个研究点目标入组 50 人开始时间: 2020年6月11日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib.
排除标准
- •Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor.
研究者
相似试验
进行中（未招募）
1 期
A multiple center expanded access program (EAP) for the treatments of patients with advanced solid tumorsEUCTR2019-002319-25-ITOXO ONCOLOGY INCORPORATED450
进行中（未招募）
不适用
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
进行中（未招募）
1 期
Access Program for Asfotase AlfaHypophosphatasiaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
已完成
不适用
MULTICENTER PROGRAM EXTENDED OPEN MODALITY OF ACCESS WITH ALPHA 2A (RO 25-8310) AS A MONOTERAPY AND COMBINATION THERAPY WITH RIVABIRIN (RO 20-9963) IN PATIENTS WITH CHRONIC HEPATITIS C-B171 Acute hepatitis CAcute hepatitis CB171PER-067-01PRODUCTOS ROCHE Q.F.S.A.,
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.